Blood test to predict response to immunotherapy
Part of Cancer clinical trials.
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have stage III or IV cancer
- Your doctor has decided to order the Episwitch CiRT® test as part of your usual care
- You are well enough to be up and about (ECOG score 0, 1, or 2)
- You are a candidate for immunotherapy (PD-1 or PD-L1 checkpoint inhibitors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is monitoring changes in a cancer protein called PD-L1 in head and neck cancer patients before and during immunotherapy treatment. It aims to better understand how well immunotherapy will work by using regular blood tests.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This study watches immune system markers to see if they can predict which patients will respond well to immunotherapy and who might have side effects. If you have cancer and are starting immunotherapy, this trial may help guide future treatment decisions.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This trial is testing a simple blood test to see if it can predict how well immunotherapy will work for people with advanced cancer. It's for those newly diagnosed with certain cancers and about to start immunotherapy as their first treatment.
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.